- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of herpes zoster and post-herpetic neuralgia
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 730KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 182KB)
Varicella zoster virus recombinant vaccine – July 2023
Varicella zoster virus recombinant vaccine: Injection [1 vial] & adjuvant substance diluent [0.5 mL vial]; Shingrix®
Last updated
1 November 2023